Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Total Current Liabilities
Nurexone Biologic Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Total Current Liabilities
$583k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
53%
|
CAGR 10-Years
31%
|
|
|
Enerflex Ltd
TSX:EFX
|
Total Current Liabilities
CA$879m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
25%
|
CAGR 10-Years
6%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Total Current Liabilities
CA$385.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
49%
|
CAGR 10-Years
29%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Total Current Liabilities
CA$349.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
16%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Total Current Liabilities
CA$530m
|
CAGR 3-Years
5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
18%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Total Current Liabilities
$502k
|
CAGR 3-Years
-56%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Total Current Liabilities?
Total Current Liabilities
583k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Total Current Liabilities amounts to 583k USD.
What is Nurexone Biologic Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
31%
Over the last year, the Total Current Liabilities growth was 0%. The average annual Total Current Liabilities growth rates for Nurexone Biologic Inc have been -32% over the past three years , 53% over the past five years , and 31% over the past ten years .
